BRAF targeted therapy after immunotherapy for patients with metastatic melanoma a review of clinical effectiveness
While the current pCODR Expert Review Committee (pERC) recommendations mainly focus on the use of immunotherapies and BRAF inhibitors (BRAFi) as first-line therapies, the optimal sequencing of BRAF targeted therapy and immunotherapy when both are considered for the treatment of advanced melanoma has...
| Main Authors: | , |
|---|---|
| Corporate Author: | |
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
2017, October 18, 2017
|
| Edition: | Version 1.0 |
| Series: | CADTH rapid response report: summary with critical appraisal
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | While the current pCODR Expert Review Committee (pERC) recommendations mainly focus on the use of immunotherapies and BRAF inhibitors (BRAFi) as first-line therapies, the optimal sequencing of BRAF targeted therapy and immunotherapy when both are considered for the treatment of advanced melanoma has yet to be determined. The purpose of this report is to evaluate the clinical effectiveness of BRAF targeted therapy in patients with BRAF mutation positive unresectable or metastatic melanoma who have received immunotherapy as their first-line option |
|---|---|
| Physical Description: | 1 PDF file (20 pages) illustrations |